129 related articles for article (PubMed ID: 9421075)
21. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma.
Caduff RF; Johnston CM; Svoboda-Newman SM; Poy EL; Merajver SD; Frank TS
Am J Pathol; 1996 May; 148(5):1671-8. PubMed ID: 8623934
[TBL] [Abstract][Full Text] [Related]
22. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: oncogene/tumor suppressor gene alterations and human papillomavirus genotyping.
Jones MW; Kounelis S; Papadaki H; Bakker A; Swalsky PA; Woods J; Finkelstein SD
Int J Gynecol Pathol; 2000 Apr; 19(2):110-7. PubMed ID: 10782406
[TBL] [Abstract][Full Text] [Related]
23. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
24. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic and Genomic Analysis of
Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
[TBL] [Abstract][Full Text] [Related]
26. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
[TBL] [Abstract][Full Text] [Related]
27. K-ras-2 and p53 genotyping of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses.
Wu TT; Barnes L; Bakker A; Swalsky PA; Finkelstein SD
Mod Pathol; 1996 Mar; 9(3):199-204. PubMed ID: 8685214
[TBL] [Abstract][Full Text] [Related]
28. Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.
Yasue A; Hasegawa K; Udagawa Y
Hum Cell; 2011 Jun; 24(2):65-73. PubMed ID: 21547354
[TBL] [Abstract][Full Text] [Related]
29. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma.
Coppola D; Fu L; Nicosia SV; Kounelis S; Jones M
Hum Pathol; 1998 May; 29(5):455-62. PubMed ID: 9596268
[TBL] [Abstract][Full Text] [Related]
31. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis.
Holst VA; Finkelstein S; Colby TV; Myers JL; Yousem SA
Am J Surg Pathol; 1997 Jul; 21(7):801-11. PubMed ID: 9236836
[TBL] [Abstract][Full Text] [Related]
32. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer.
Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W
Gynecol Oncol; 1999 Sep; 74(3):468-71. PubMed ID: 10479512
[TBL] [Abstract][Full Text] [Related]
33. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
34. K-ras exon 2 point mutations in human endometrial cancer.
Semczuk A; Schneider-Stock R; Berbec H; Marzec B; Jakowicki JA; Roessner A
Cancer Lett; 2001 Mar; 164(2):207-12. PubMed ID: 11179836
[TBL] [Abstract][Full Text] [Related]
35. Low frequency of BRAF and CDKN2A mutations in endometrial cancer.
Salvesen HB; Kumar R; Stefansson I; Angelini S; MacDonald N; Smeds J; Jacobs IJ; Hemminki K; Das S; Akslen LA
Int J Cancer; 2005 Jul; 115(6):930-4. PubMed ID: 15723290
[TBL] [Abstract][Full Text] [Related]
36. Prediction of Biologic Aggressiveness in Colorectal Cancer by p53/K-ras-2 Topographic Genotyping.
Finkelstein SD; Przygodzki R; Pricolo VE; Sakallah SA; Swalsky PA; Bakker A; Lanning R; Bland KI; Cooper DL
Mol Diagn; 1996 Jun; 1(1):5-28. PubMed ID: 10330194
[TBL] [Abstract][Full Text] [Related]
37. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.
Tortola S; Marcuello E; González I; Reyes G; Arribas R; Aiza G; Sancho FJ; Peinado MA; Capella G
J Clin Oncol; 1999 May; 17(5):1375-81. PubMed ID: 10334521
[TBL] [Abstract][Full Text] [Related]
38. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
Fukuyama Y; Mitsudomi T; Sugio K; Ishida T; Akazawa K; Sugimachi K
Br J Cancer; 1997; 75(8):1125-30. PubMed ID: 9099959
[TBL] [Abstract][Full Text] [Related]
39. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
40. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]